The changes to the fact sheet include recommendations to vaccination providers about giving the J&J shot to people with existing medical conditions, including those who have a low level of platelets, a type of blood cell that helps stop bleeding.
The reality sheet for Johnson and Johnson’s Covid-19 vaccine has been reexamined by U.S. regulators to caution of the risk of an uncommon bleeding problem. The Food and Drug Administration said in a letter to the organization on Tuesday that adverse-event reports proposed an expanded danger of immune thrombocytopenia during the 42 days following immunization. Symptoms include bruising or exorbitant or surprising bleeding, as per the agency. Up until this point, around 17 million Americans have been given the one-dose vaccine. Last month, the CDC suggested messenger RNA vaccines made by Moderna Inc. what’s more Pfizer Inc. for use in grown-ups over J&J’s shot.
A spokesperson for J&J couldn’t immediately be reached for comment.
J&J’s vaccine has also been previously connected to rare but serious blood clots, a condition called thrombosis with thrombocytopenia syndrome, or TTS. Women ages 30 to 49 were at the highest risk, according to the Centers for Disease Control and Prevention.
For Latest News Follow us on Google News
- Show all
- Trending News
- Popular By week